With subscriber counts gone, Netflix bets big on ads--and Wall Street is loving it

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: DEEPSEEK: After the Trump administration moved to restrict Nvidia’s (NVDA) sale of A.I. chips to China, it also is weighing penalties that would block DeepSeek, China’s artificial intelligence star, from buying U.S. technology and is debating barring Americans’ access to its services, three peopl

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate,

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Amkor Technology, Inc. (NASDAQ:AMKR) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Millrose Properties, Inc. (NYSE:MRP) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]

Chinese airlines can’t afford to pay more than twice the regular price for Boeing jets, but they also can’t simply buy them from competitor Airbus.

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno

The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.

We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Noble Corporation plc (NYSE:NE) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide amid growing […]